Friday, November 21, 2025 9:30:10 AM
It won’t be declined,fda approves everything,this time was classified as “A class request “ FDA told them exactly what to fix(it’s common to have multiple labeling/side effect insert sheet changes to just change some words)most are approved around 20 days (12-30 days,”A class “is top of list turn around time) OTLK is hiring ppl here in USA to monitor the drugs side effects when ppl take it(they wouldn’t do that unless they knew it was going to mkt!) Germany/Europe/uk ,also hiring many positions,reps. To promote it! They have the largest drug manufacturer and distributor(ticker COR) in the world to get it into pharmacies, they have all their ducks in a row,this is happening and don’t believe the buyout b/s ,OTLK is taking it to mkt and planning on making tons of profit
Recent OTLK News
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 06/02/2026 01:31:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/02/2026 01:30:12 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/01/2026 09:00:43 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/01/2026 09:00:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/01/2026 01:15:32 PM
- Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) • GlobeNewswire Inc. • 06/01/2026 12:46:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2026 08:30:49 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/29/2026 12:30:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2026 09:09:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/27/2026 07:29:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/27/2026 07:24:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/26/2026 11:15:41 AM
- Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg) • GlobeNewswire Inc. • 05/26/2026 11:00:00 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2026 09:03:14 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 08:31:12 PM
- Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/15/2026 08:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/13/2026 09:12:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 08:36:26 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 05/07/2026 08:24:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/23/2026 08:30:39 PM
- Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering • GlobeNewswire Inc. • 04/23/2026 08:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/23/2026 11:30:17 AM
- Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/21/2026 08:15:44 PM
- Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) • GlobeNewswire Inc. • 04/21/2026 01:05:00 PM
